← Leaderboards
Gregory D Cuny
Brigham And Women'S Hospital
$9,699,952
Attributed
$13,675,798
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,675,798 · 11
By mechanism
R01$8,265,543 · 3
U24$2,299,596 · 1
R56$1,346,411 · 2
R21$1,291,072 · 3
U01$272,424 · 1
R41$200,752 · 1
Top collaborators
- Alexei Degterev9 shared
- Siddharth Balachandran6 shared
- Marcie A Glicksman3 shared
- Ming Hu1 shared
- Yukari Perrella1 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Heinz Gernot Remold$5,969,545
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoSeriesIn VitroCellsMediatingPathway InteractionsAcuteAnalogInhibitor/AntagonistChronicToxic EffectDrug KineticsMouse ModelSmall MoleculePhosphotransferasesProgramsInfectionCell DeathBaseApoptosisPropertyNecrosisAffectDesign
Grant awards (22)
Systemic and gastrointestinal targeted CDPK1 inhibitors for cryptosporidiosis$812,603
R01 · FY2025 · AI · contact PI
Targeting RIPK3 in Flu-Associated Lung Injury$702,005
R01 · FY2023 · AI
Targeting RIPK3 in Flu-Associated Lung Injury$731,691
R01 · FY2022 · AI
Degrader probes for necroptosis pathway$197,400
R21 · FY2022 · AI · contact PI
Targeting RIPK3 in Flu-Associated Lung Injury$789,265
R01 · FY2021 · AI
Degrader probes for necroptosis pathway$250,500
R21 · FY2021 · AI · contact PI
IMPDH inhibitors for the treatment of Cryptosporidium infections$746,322
R01 · FY2020 · AI · contact PI
Targeting RIPK3 in Flu-Associated Lung Injury$678,878
R01 · FY2020 · AI
IMPDH inhibitors for the treatment of Cryptosporidium infections$766,043
R01 · FY2019 · AI · contact PI
Targeting RIPK3 in Flu-Associated Lung Injury$719,078
R01 · FY2019 · AI
Targeting RIPK1 and RIPK2 kinases in mouse Experimental Autoimmune Encephalomyelitis$457,880
R21 · FY2019 · NS
IMPDH inhibitors for the treatment of Cryptosporidium infections$756,794
R01 · FY2018 · AI · contact PI
Targeting RIPK3 in Age-Related Inflammation and Injury$648,995
R56 · FY2018 · AG
IMPDH inhibitors for the treatment of Cryptosporidium infections$759,898
R01 · FY2017 · AI · contact PI
IMPDH inhibitors for the treatment of Cryptosporidium infections$802,966
R01 · FY2016 · AI · contact PI
Optimizing IMPDH inhibitors for the treatment of cryptosporidiosis$697,416
R56 · FY2014 · AI · contact PI
CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease$200,752
R41 · FY2012 · AG
Small Molecule Modulators of the Glutamate Transporter for Treatment of ALS$38,918
U01 · FY2012 · NS
Small Molecule Modulators of the Glutamate Transporter for Treatment of ALS$233,506
U01 · FY2011 · NS
Small molecule probes for elucidating necrotic cell death mechanisms$103,250
R21 · FY2011 · NS · contact PI
National Center for Drug Discovery in Neurodegeneration$2,299,596
U24 · FY2009 · NS · contact PI
Small molecule probes for elucidating necrotic cell death mechanisms$282,042
R21 · FY2009 · NS · contact PI